TABLE 2.
Disease Characteristics of Evaluated Patients by Disease Type
| Disease Type | Disease Location | Phenotype | Disease Duration (years) | Other Extraintestinal Manifestations | Steroid Prescription | Biologic Prescription | Endoscopic Activity | Prior Surgery for IBD | Hospitalization for Flare Within Past 6 Months |
|---|---|---|---|---|---|---|---|---|---|
| CD | Small bowel: 73 (29%) Large bowel: 42 (17%) Small and large bowel: 115 (46%) Pan-gut: 15 (6%) Perianal only: 4 (2%) | Stricturing:51 (21%)Perianal/Fistulizing: 120 (51%) | 3818 | Arthritis: 33 (13%) EN: 18 (7%) PG: 4 (2%) PSC: 3 (1%) Iritis/Uveitis: 17 (7%) | 21% | 62% | 75% (n = 223) | 57% | 29% |
| UC | Proctitis: 7 (7%) Left sided: 34 (33%) Pancolitis: 61 (60%) | ~ | 1410 | Arthritis: 5 (5%) EN: 1 (1%) PG: 0 PSC: 4 (4%) Iritis/Uveitis: 1 (1%) | 37% | 55% | 89% (n = 94) | 7% | 24% |
| Combined | ~ | ~ | 3715 | Arthritis: 38 (11%) EN: 19 (5%) PG: 4 (1%) PSC: 7 (2%) Iritis/Uveitis: 18 (5%) | 26% | 60% | 79% | 43% | 27% |
For disease location, pan-gut includes patients with upper gastrointestinal disease, and patients are only counted once. Most patients had active endoscopic disease and more than a quarter of included patients were on steroids and had been hospitalized within the past month. About half of patients with CD had perianal or fistulizing disease. ABC represents the lower quartile A, the median B, and the upper quartile C.
n, number of patients for whom endoscopic data were available; EN, erythema nodosum; PG, pyoderma gangrenosum; PSC, primary sclerosing cholangitis.